Innovent doses first patient in pivotal colorectal cancer study
August 06, 2026 | 09:49
Innovent Biologics, listed under HKEX code 01801, dosed the first patient in a pivotal registrational study of IBI363/TAK-928 combined with bevacizumab for late-line advanced colorectal cancer in China.
Mobile Version